Table 4.
Summary of adrenal function in patients without AI in malignancy.
| Controls | Cancer, no metastases | U/L adrenal metastasis | B/L adrenal metastases but no AI | Disseminated malignancy | AI | |
|---|---|---|---|---|---|---|
| Baseline Cortisol | ||||||
| Lutz et al [31] | 307.4 ± 33.2 nmol/L | 477.5 ± 64.9 nmol/L | 440.4 ± 53.5 nmol/L | 637.6 ± 92.1 nmol/L | - | - |
| Redman et al [30] | - | - | - | 582 nmol/L | - | 656 nmol/L |
| Cedermark et al [9] | - | 490 ± 24 nmol/L (well patients) 1044 ± 132 nmol/L |
- | - | - | - |
| Cedermark et al [28] | - | - | - | 862.5 nmol/L | - | - |
| Ross et al [33] | - | - | - | - | NSCLC 432 nmol/L SCLC 212 nmol/L |
- |
| Individual cases of AI from Table 1 | - | - | - | - | - | 318 ± 237 nmol/L |
| Stimulated cortisol or increase in cortisol | ||||||
| Lutz et al [31] | 794.6 ± 41.2 nmol/L | 939.7 ± 99.2 nmol/L | 990.8 ± 92.9 nmol/L | 1151.4 ± 155.5 nmol/L | - | - |
| Redman et al [30] | - | - | - | 480 nmol/L (increase from baseline) | - | 35 nmol/L (increase from baseline) |
| Cedermark et al [9] | - | 930 ± 43 nmol/L (well patients) 1339 ± 117 nmol/L (unwell patients) |
- | - | - | - |
| Cedermark et al [28] | - | - | - | 1137.5 nmol/L (mean stimulated cortisol) 225 nmol/L (mean increase from baseline) |
- | - |
| Ross et al [33] | - | - | - | - | 828.5 (536–1675) nmol/L (median for both groups) | - |
| Individual cases of AI from Table 1 | - | - | - | - | - | 423 ± 238 nmol/L |
U/L = unilateral; B/L = bilateral; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.